Bone Growth Factor Market Offers Attractive Niche For Medtronic

Medtronic/Sofamor Danek expects to submit clinical data supporting a premarket approval application for its InFuse BMP-2 recombinant bone morphogenic protein by mid-year. The company is hoping for expedited FDA review of the product, with a possible rollout by 2002.